b 2 -Adrenoceptor agonists are potent bronchodilators and are widely used in the treatment of asthma. However, the continuous or repeated exposure to these drugs reduces the bronchodilation mediated by b 2 -adrenoceptors. The mechanism of the reduced responsiveness to b 2 -adrenoceptor agonists has been studied extensively. Nowadays, the uncoupling of b 2 -adrenoceptor to G s protein and down-regulation of the receptor are recognized as the key process in the phenomenon.
b 2 -Adrenoceptor agonists are potent bronchodilators and are widely used in the treatment of asthma. However, the continuous or repeated exposure to these drugs reduces the bronchodilation mediated by b 2 -adrenoceptors. The mechanism of the reduced responsiveness to b 2 -adrenoceptor agonists has been studied extensively. Nowadays, the uncoupling of b 2 -adrenoceptor to G s protein and down-regulation of the receptor are recognized as the key process in the phenomenon. 1) Thus, the number of receptors expressed in the airway smooth muscle cell appears to be important in determining the response to stimulation of b 2 -adrenoceptor.
Previous reports demonstrated that increasing expression of b 2 -adrenoceptors in stably transfected cells increased basal cAMP levels and the potency of isoproterenol in stimulating cAMP formation. [2] [3] [4] However, the influence of receptor number of b 2 -adrenoceptor on cAMP response evoked by the direct activation of adenylyl cyclase has not been clearly addressed. The purpose of this study, therefore, was to examine how density of b 2 -adrenoceptor affects the forskolin-induced cAMP accumulation in Chinese hamster ovary (CHO) cells transfected with human b 2 -adrenoceptor.
MATERIALS AND METHODS
The cDNA encoding human b 2 -adrenoceptor was kindly provided by Dr. R. J. Lefkowitz (Duke University). For expression, the human b 2 adrenoceptor cDNA was inserted into pEF/myc/cyto (Invitrogen Corp., Carlsbad, Calif., U.S.A.) at the NcoI and SalI restriction sites. Chinese hamster ovary cells (CHO-K1 cells) were transfected with pEF/myc/cyto-b 2 using lipofectAMINE (Life Technologies, Grand Island, NY, U.S.A.) according to the manufacturer's instructions. Clones were isolated by selection with G418 (1 mg/ml) and were screened for b 2 -adrenoceptor expression in a [
3 H]CGP 12177 radioligand binding assay as described below. Culture medium was Ham's F-12 Nutrient mixture supplemented with 10% of fetal bovine serum.
Membrane Preparation Stably expressed CHO cells were grown to ca. 80% confluence at 37°C in 5% CO 2 /95% humidified air. The cells were washed, and scraped into icecold lysis buffer, and homogenized at 20000 rpm for 60 s with the tissue homogenizer. The lysis buffer consisted of 10 mM Tris-HCl (pH 7.4) containing 5 mM EDTA, 5 mM EGTA, 2.5 mg/ml pepstatin A, 0.1 mM phenylmethylsulfonyl fluoride and 1 mM leupeptin. Membranes were pelleted at 45000ϫg for 30 min and resuspended in 10 mM HepesNaOH (pH 7.4) to give a final concentration of 1 mg/ml and stored at Ϫ80°C until the receptor binding assay was carried out.
Radioligand Receptor Binding Assay Radioligand receptor binding studies were conducted in reaction buffer containing 50 mM Tris-HCl (pH 7.4) and 10 mM MgCl 2 at 37°C for 60 min using 50 mg of membrane protein. For saturation isotherms, membranes were incubated with various concentrations (0.2-6.8 nM) of [ 3 H]CGP 12177 (37 Ci/mmol, NEN Life Science Products, Inc., Boston, MA, U.S.A.) with or without propranolol (10 mM) for 60 min. Reactions were terminated with rapid filtration though Whatman GF/C glass filters (Whatman plc, Kent, U.K.) using a Brandel cell harvester (model M-12, Brandel, Gaithersburg, MD, U.S.A.). The filters were washed three times with the ice-cold buffer. They were placed in liquid scintillation counting vials containing 4 ml of Clear-sol I (Nacalai Tesque, Kyoto, Japan). Radioactivity was measured in a liquid scintillation counter (LS6000 IC, Beckman Instruments, Calif., U.S.A.). Saturation curves were analyzed using the GraphPad Prism program (GraphPad Software, San Diego, Calif., U.S.A. 5, 6) and the vehicle were added to the wells during this 30 min incubation period. After exposing the cells to forskolin or isoproterenol for 10 min, the incubation buffer was removed, and reactions were stopped by adding 1 ml of ice-cold 6% trichloroacetic acid. The cells were scraped and the cell suspensions were transferred to tubes. The samples were sonicated for 5 min and centrifuged at 1500ϫg for 10 min at 4°C. The cyclic AMP containing supernatant was extracted with 5 ml of water-saturated diethyl ether. We determined the cAMP content using a method of radioimmunoassay (cAMP assay kit, Yamasa Shoyu, Choshi, Japan).
Statistics Data were expressed as meansϮS.E.M. and were analyzed using either Student's t-test or Tukey's multiple comparison test after one-way analysis of variance. A p value less than 0.05 was considered significant.
Drugs The following drugs were used: G418 disulfate (Nacalai Tesque, Kyoto, Japan), forskolin (Research Biochemicals International, Natick, MA, U.S.A.). Figure 1 shows the influence of b 2 -adrenoceptor density on basal and forskolin-stimulated cAMP accumulation. In CHO cells expressing the b 2 -adrenoceptor, the basal levels of cAMP were higher than in CHO cells that were transfected with pEF/myc/cyto (Mock). Both basal and forskolin-stimulated cAMP accumulation obtained in the higher expressing cell line CHO-b 2 /H were larger than those in the lower expressing CHO-b 2 /L cell line.
RESULTS
As shown in Fig. 2A , ICI 118,551 markedly reduced basal cAMP production in both CHO-b 2 /H and CHO-b 2 /L cells. In addition, ICI 118,551 attenuated the forskolin-and isoproterenol-stimulated cAMP accumulation (Figs. 2B, C) .
DISCUSSION
Previous study demonstrated that increase in b 2 -adrenoceptor number resulted in an enhanced both basal and isoproterenol-induced cAMP production, that was inhibited by a b 2 -adrenoceptor antagonist (ICI 118,551) with inverse agonist activity. 4) In the present study, we have shown that forskolin-induced cAMP accumulation was also augmented by stable expression of b 2 -adrenoceptor. The enhanced cAMP responses to forskolin were attenuated by treatment with ICI 118,551. These results suggest that the agonist-independent (constitutive) activity of b 2 -adrenoceptor plays an important role in modulating cAMP responses produced by activation of adenylyl cyclase.
Reconstitution of adenylyl cyclase isoenzyme with purified G s a protein subunits exhibited a synergistic effect on the forskolin-induced adenylyl cyclase activation. 7) Therefore, the increased level of free G s a subunits due to expression of G s protein-coupled receptors with constitutive activity would enhance the responses to forskolin. Alewijnse et al. 8) demonstrated that constitutive activity of G s protein-coupled receptors, such as histamine H 2 receptor and thyrotropin receptor, contribute to the enhancement of both basal and forskolin-induced cAMP production in CHO cells. They also observed similar augmentations when human embryonic kidney (HEK)-293, African green monkey kidney (COS)-7 or Sf9 cells were used instead of CHO cells. 8) Additionally, in studies using the cells endogenously expressing b 1 -adrenoceptor, propranolol attenuated the forskolin-mediated responses.
9,10) These results strongly suggest that the enhance- ment of forskolin-induced cAMP production is a general characteristic of G s protein-coupled receptors with constitutive activity. In regard to b 2 -adrenoceptors, constitutive activity has been demonstrated following site directed mutagenesis 6) or overexpression of the receptor [4] [5] [6] and transgenic mice.
11) Indeed, the number of b 2 -adrenoceptors expressed in CHO cells in this study was relatively higher than that of endogenously expressing the receptor (ca. 100 fmol/mg protein).
12) Thus, it is likely that the higher expression levels of b 2 -adrenoceptors exhibits the notable constitutive activity and thereby enhance forskolin-induced cAMP response.
Although b 2 -adrenoceptor agonists are potent bronchodilators and widely used in the treatment of asthma, the continuous or repeated exposure to these drugs reduces bronchodilation mediated by b 2 -adrenoceptors. In these situations, to reduce the dose of b 2 -adrenoceptor agonists, combining b 2 -adrenoceptor agonists with methylxanthines (e.g., theophylline) has traditionally been conducted. The present results indicate that elevation of b 2 -adrenoceptor density leads to the enhancement of responses evoked by direct activation of adenylyl cyclase, as well as stimulation of b 2 -adrenoceptor. Therefore, if expression of b 2 -adrenoceptor is locally controlled in the respiratory system, such gene therapy may become the novel clinical strategy to improve airflow limitation in asthma.
In conclusion, increasing expression of b 2 -adrenoceptors enhances not only basal and isoproterenol-induced cAMP production but also forskolin-induced one. The enhancement seems to be attributable to the constitutive activity of b 2 -adrenoceptors.
